Study: Tykerb plus Herceptin far better than single drug; Roche readies for first Raptiva trial;

 @FiercePharma: Launch angst among investors, analysts say: 'People are all freaked out'--Reuters. Article | Follow @FiercePharma

> The combination of GlaxoSmithKline's ($GSK) Tykerb and Roche's ($RHHBY) Herceptin was almost two times as effective for invasive breast cancer as single-drug therapy. News

> Roche's Genentech unit is prepping for a Jan. 30 trial of claims that its psoriasis drug Raptiva caused fatal infections in some patients. Report

> A union fund sued Walgreen Co. and Par Pharmaceuticals, alleging that they conspired to overcharge for generic drugs. Story

> The World Health Organization warned India that IMS Health data used to gauge drug prices presents "a major problem" because it doesn't account for rebates and other discounts. Article

> Denmark's Lundbeck launched its antipsychotic drug Sycrest in the U.K. for bipolar I; it's sold as Saphris in the U.S. by Merck ($MRK). Report

> The influential labor union AFSCME has targeted Johnson & Johnson ($JNJ) as part of its proxy campaign to split the roles of chairman and chief executive at 7 major companies. News

> China's Sanjiu Pharma plans to spend 600 million to 700 million yuan on a 99% stake in Shandong Sunfeng Pharamceutical to augment its medicated skincare market, Shanghai Securities reports. More

> Indian drugmaker Dishman Pharmaceuticals said its Swiss unit bought the French contract research and manufacturing company Creapharm Parenterals. Article

> Dishman Netherlands inked a deal with Charles Bowman and Co. to distribute Vitamin D3 products in North America. Story

Biotech News

@FierceBiotech: Constellation inks $95M discovery deal, buyout option with Genentech on new epigenetic drug programs. News | Follow @FierceBiotech

@JohnCFierce: Say goodnight, gracie. Dimebon fails final Ph3, Pfizer dumps monster partnership. Release | Follow @JohnCFierce

@MarkHFierce: Researchers are challenging studies that linked hormone replacement therapy to cancer based on "flawed" data. More | Follow @MarkHFierce

> The 10 biotech IPOs of 2011. Report

> Fledgling Verastem outlines investor strategy behind high-risk $50M IPO. Story

> Constellation inks $95M discovery deal, buyout option with Genentech. News

Biotech Research News

> Sugar molecules betray precancerous cells in esophagus. More

> Hormone irisin eyed as possible weight loss drug ingredient. Item

> Vitamin D helps (more than) 3 (nearly) blind mice see. Article

> PARP inhibitors could aid larger ovarian cancer patient population. News

> Altering intestional bacteria with probiotics improved rats' heart health. Story

Manufacturing News

> Roche pilots direct shipments to Europe. News

> Abbott dodges excise tax at Indian plant. Story

> Daiichi sends Japanese execs to new Ranbaxy plant in India. More

> FDA: Novartis plant shows patterns of problems. Story

> USP has credibility as pedigree driver. Article

IT News

> Cannabis company launches Jane-Ome app. Item

> PerkinElmer CEO arranges marriage between informatics, lab service biz. More

> Entelos stages comeback bid with funding. Article

> AB Sciex, Indigo BioSystems join forces on mass spectrometry software. Story

> DecisionView updates clinical trial enrollment software. News

And Finally... A new "smart pill" that notifies patients about drug doses is set for sale in the U.K. this fall. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.